- Home
- PBYI vs VACI Comparison
PBYI vs VACI Comparison
Compare PBYI & VACI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$7.61
N/A
Current Price
$9.97
Company Overview
Basic Information| Metric | PBYI | VACI |
|---|---|---|
| Founded | 2010 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.4M | 312.3M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | PBYI | VACI |
|---|---|---|
| Price | $7.61 | $9.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 370.3K | 78.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.78 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $27,685,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.58 | $9.86 |
| 52 Week High | $7.68 | $10.07 |
Technical Indicators
Market Signals| Indicator | PBYI | VACI |
|---|---|---|
| Relative Strength Index (RSI) | 69.82 | 50.85 |
| Support Level | $6.32 | $9.94 |
| Resistance Level | N/A | $10.06 |
| Average True Range (ATR) | 0.29 | 0.02 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 93.89 | 30.00 |
Price Performance
Historical Comparison PBYI
VACI
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About VACI Viking Acquisition Corp. I Class A Ordinary Shares
Viking Acquisition Corp I is a blank check company.